Sign in

    ZimVie Inc (ZIMV)

    Q1 2024 Earnings Summary

    Reported on Apr 3, 2025 (After Market Close)
    Pre-Earnings Price$15.38Last close (May 8, 2024)
    Post-Earnings Price$18.32Open (May 9, 2024)
    Price Change
    $2.94(+19.12%)
    • ZimVie is experiencing approximately 50% growth in their guided surgery line, which is seeing great adoption and very high renewal rates, indicating strong growth potential in this segment.
    • The company is implementing significant cost reductions in corporate infrastructure, legal, and IT expenses, and has already taken a large portion out, which will support their goal to reach 15% EBITDA margin by April 1, 2025, potentially even sooner.
    • Despite macroeconomic challenges, customer retention remains strong due to the "sticky" nature of their digital products, and they expect market stabilization in the back half of the year to position them well for growth.
    • ZimVie is experiencing declining sales in the U.S. implant market, indicating continued challenges in this key segment.
    • Lower sales of the iTero product line have put pressure on the company's capital sales, affecting revenue growth.
    • A decline in same-store sales suggests reduced purchasing from existing customers, potentially reflecting underlying demand issues.
    1. 15% EBITDA Margin Timing
      Q: When will you achieve the 15% EBITDA margin target?
      A: We expect to reach the 15% EBITDA margin by April 1, 2025, one year after the sale of our spine business.

    2. Operational Drivers for EBITDA Growth
      Q: What are the key drivers to reach the EBITDA target?
      A: We're reducing corporate infrastructure costs, particularly in legal and IT expenses, and optimizing manufacturing operations to improve efficiency and margins.

    3. Impact of Mix on Revenue
      Q: How are shifts in mix affecting revenue, and how will you improve it?
      A: Unfavorable product mix, due to lower iTero capital sales and challenges in the U.S. implant market, has pressured revenue. We're focusing on our strong digital solutions and biomaterials portfolios to drive improvement. Pricing remains stable, down only about 1%.

    4. Digital Revenue and Market Stabilization
      Q: How is digital revenue performing amid market softness?
      A: Our digital products, especially guided surgery, are showing nearly 50% growth and are highly valued by customers. While same-store sales have declined, we're retaining customers and expect market stabilization later in the year.